Reported results
- Net loss was $16.5 million for the third quarter of 2026 and $2.4 million for the first nine months of 2026.
- Total revenue was $0.6 million for the third quarter of 2026 and $52.7 million for the first nine months of 2026.
- Basic and diluted net loss per ordinary share was $0.32 for the third quarter of 2026 and $0.05 for the first nine months of 2026.
- Research and development expenses totaled $8.4 million for the third quarter of 2026 and $29.9 million for the first nine months of 2026.
- General and administrative expenses totaled $10.6 million for the third quarter of 2026 and $34.2 million for the first nine months of 2026.
- Cash, cash equivalents and restricted cash position was $272.2 million as of September 30, 2026.
Guidance
- Full year 2026 net cash used in operating and investing activities is expected to be $18 to $23 million.
- The company expects to end 2026 with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash.
- Estimated full year 2026 net loss is expected to be $25 to $30 million.
- Estimated full year 2026 net loss includes an estimated $26 million of non-cash share-based compensation expense.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
